Michal Nisnboym
Overview
Explore the profile of Michal Nisnboym including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong Z, Walsh K, Sneiderman C, Nisnboym M, Hadjipanayis C, Agnihotri S, et al.
Neuro Oncol
. 2025 Feb;
PMID: 39949048
Background: Individual-level characteristics underlying population-level variation in glioma risk and outcomes remain incompletely understood. Cancer immunosurveillance, host immunity, and some immunotherapies center on the ability of an individual's immune cells...
2.
Nisnboym M, Sneiderman C, Jaswal A, Xiong Z, Vincze S, Sever R, et al.
Expert Rev Clin Immunol
. 2024 Oct;
21(2):239-247.
PMID: 39402706
Background: Glioblastoma (GBM) is an aggressive cancer with limited treatment options. Immunotherapy targeting CD69, an early activation marker on T cells, has shown promise in preclinical models of non-CNS malignancies....
3.
Raphael I, Mujeeb A, Ampudia-Mesias E, Sever R, McClellan B, Frederico S, et al.
bioRxiv
. 2024 Sep;
PMID: 39314283
Statement Of Significance: We demonstrate mechanisms of the druggable glioma-derived CD200 checkpoint on tumor growth and immune suppression.
4.
Frederico S, Raphael I, Nisnboym M, Huq S, Schlegel B, Sneiderman C, et al.
Expert Rev Clin Immunol
. 2024 Aug;
20(11):1411-1420.
PMID: 39114885
Objectives: Despite surgical resection, chemoradiation, and targeted therapy, brain tumors remain a leading cause of cancer-related death in children. Immunotherapy has shown some promise and is actively being investigated for...
5.
Vincze S, Jaswal A, Frederico S, Nisnboym M, Li B, Xiong Z, et al.
Sci Rep
. 2024 Mar;
14(1):5305.
PMID: 38438420
Glioblastoma (GBM) is the most common primary malignant brain tumor. Currently, there are few effective treatment options for GBM beyond surgery and chemo-radiation, and even with these interventions, median patient...
6.
Gadoth A, Nisnboym M, Alcalay Y, Zubkov A, Schwartz I, Schwartz D, et al.
Neurol Neuroimmunol Neuroinflamm
. 2023 Aug;
10(6).
PMID: 37591767
Background And Objectives: Antileucine-rich glioma-inactivated 1 (anti-LGI1) autoimmune encephalitis was first described in 2010 and is today the most common type of limbic encephalitis. During the course of the disease,...
7.
Nisnboym M, Vincze S, Xiong Z, Sneiderman C, Raphael R, Li B, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1173-1188.
PMID: 37426447
Significance: Immunotherapy may hold promise for the treatment of some patients with GBM. There is a need to assess therapy responsiveness to allow the continuation of effective treatment in responders...
8.
Segal Y, Nisnboym M, Regev K, Arnon K, Kolb H, Fahoum F, et al.
Neurol Neuroimmunol Neuroinflamm
. 2023 Mar;
10(3).
PMID: 36973076
Background And Objectives: To explore the clinical characteristics and HLA associations of patients with anti-leucine-rich glioma-inactivated 1 encephalitis (LGI1E) from a large single center in Israel. Anti-LGI1E is the most...